• Explore /
  • Poster
  • / Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate as neoadjuvant therapy for osteosarcoma: A single-arm, exploratory phase II trial.

Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate as neoadjuvant therapy for osteosarcoma: A single-arm, exploratory phase II trial.

Abstract Poster

Authors

null

Qinglian Tang

Sun Yat-Sen University Cancer Center, Guangzhou, China

Qinglian Tang , Xiaojun Zhu , Guohui Song , Jinchang Lu , Hao Wu , Huaiyuan Xu , Xin-ke Zhang , Fei Ai , Yingchun Zhang , Jin Wang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Bone Tumors

Clinical Trial Registration Number

NCT04294511

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 11526)

DOI

10.1200/JCO.2023.41.16_suppl.11526

Abstract #

11526

Poster Bd #

460

Abstract Disclosures

Similar Posters

First Author: Lu Xie

First Author: Ariel Nash

First Author: Wenxi Yu

First Author: Elizabeth R. Plimack